Shots:

• The approval is based on pivotal P- II VISION study that involves assessing of Tepmetko (450mg- qd) as monothx. in 152 patients with a median age of 73 years with advanced/ m-NSCLC with METex14 skipping alterations
• Results: treatment-naïve patients & previously treated patients- ORR (43% & 43%); mDoR (0.8 and 11.1mos.); DoR @6mos. (67% & 75%); DoR @9mos. (30% & 50%) respectively
• Tepmetko is an oral MET inhibitor that inhibits the oncogenic MET receptor signaling caused by MET (gene) alterations and approved for both treatment naïve and previously treated METex14 positive NSCLC patients

 ­ Ref: PRNewswire | Image: Merck KGaA